United States

AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

27 Jun 2017
Change (% chg)

$-0.05 (-2.22%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ACRX.O


AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product... (more)


Beta: 2.73
Market Cap(Mil.): $102.11
Shares Outstanding(Mil.): 45.38
Dividend: --
Yield (%): --


  ACRX.O Industry Sector
P/E (TTM): -- 242.00 19.11
EPS (TTM): -1.05 -- --
ROI: -53.00 -8.00 -5.00
ROE: -2,520.57 -10.45 -4.24

BRIEF-Acelrx Pharmaceuticals updates on notification from U.S. FDA

* U.S. FDA notified co that it no longer plans to hold an advisory committee meeting in connection with its review of NDA for Dsuvia

Jun 07 2017

BRIEF-Acelrx Pharmaceuticals files for mixed shelf of up to $150 mln

* Acelrx Pharmaceuticals Inc files for mixed shelf of up to $150.0 million - sec filing Source text - http://bit.ly/2ruEt7F Further company coverage:

Jun 05 2017

BRIEF-Acelrx Pharmaceuticals CFO Timothy Morris resigns

* Acelrx Pharmaceuticals - on June 2, CFO Timothy E. Morris notified co of his resignation from all positions with co effective immediately - SEC filing

Jun 05 2017

BRIEF-AcelRx Pharmaceuticals reports Q1 total revenue $3.1 million

* AcelRx Pharmaceuticals reports first quarter 2017 financial results and provides corporate update

May 08 2017

BRIEF-AcelRx Pharma says DSUVIA resulted in 3-point reduction in pain intensity within 60 minutes of administration

* AcelRx Pharmaceuticals presenting comprehensive DSUVIA clinical trial results at ASRA's annual regional anesthesiology and acute pain medicine meeting

Apr 06 2017

BRIEF-European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil

* European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil 30 mcg tablet (ARX-04) for moderate-to-severe acute pain

Mar 28 2017

BRIEF-Acelrx Pharmaceuticals Q4 loss per share $0.21

* Acelrx Pharmaceuticals reports fourth quarter and year end 2016 financial results

Mar 02 2017

BRIEF-Acelrx says U.S. app to market painkiller Dsuvia accepted by FDA

* Acelrx pharmaceuticals' new drug application for dsuvia accepted for filing with pdufa date of october 12, 2017

Feb 27 2017

BRIEF-Acelrx Pharmaceuticals appoints Vincent Angotti as CEO

* Acelrx Pharmaceuticals appoints Vincent J. Angotti chief executive officer

Feb 16 2017

More From Around the Web

Earnings vs. Estimates